Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like AI-supported mammography improves early detection of breast cancer January 30, 2026 Primary care: Patients value speedy portal responses over in-person appointments January 27, 2026 Stroop-CN: A rapid diagnostic tool for minimal hepatic encephalopathy July 19, 2024